Prostate cancer is rising on a noticeable percentage among people. Changing lifestyle is impacting the health and drug manufacturers are focused on development of new effective solution.

Report coverage

Market	Abiraterone Acetate Drugs Market
Analysis Period	2017 - 2028
Base Year	2020
Forecast Data	2021 - 2028
Segments Covered	By Dosage Form, By Strength, By Distribution Channel, and By Region
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Janssen Global Services, LLC, Dr Reddy's Laboratories, Avalon Pharma Pvt Ltd, Amneal Pharmaceuticals, Sterling S.P.A. IT, Aurisco Pharmaceutical, Teva Pharmaceutical Industries Ltd, ScinoPharm Taiwan, Hetero Healthcare Limited, Qilu Pharmaceutical, Genex Pharma, and Mylan N.V.
Report Coverage	Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis
Customization Scope	10 hrs of free customization and expert consultation

Market Dynamics

Rising number of patient in hospitals suffering from prostate cancer and rapid advancements in medical sector to deliver the advanced solutions are major factors expected to drive the growth of global abiraterone acetate drugs market. Changing lifestyle pattern and high consumption of unhealthy food is impacting the health. More than 3.1 million men in the United States have been diagnosed with prostate cancer. In 2021 about 248,530 new cases of prostate cancer have been detected. Major players are investing high for the development of advanced solution. Their consistent efforts towards increasing the clinical trials and develop new drugs. This is expected to impact the growth of target market.

In 2018, the FDA accepted the approval of Janssen Biotech Inc. for abiraterone acetate “Zytiga” tablets in combination with prednisone for metastatic high-risk castration-sensitive prostate cancer (CSPC). This oral medication is expected to aid patient from prostate cancer issues.

In 2021, Amneal Pharmaceuticals, Inc, a global pharmaceutical company received approval from FDA for additional strength of 500 mg to its Abbreviated New Drug Application (ANDA). Abiraterone Acetate Tablets, USP, 250 mg and 500 mg is approved for its use in combination with Prednisone. This is expected to help company to attract new customers and increase the customer base.

In 2019, Hikma Pharmaceuticals PLC, a global drug manufacturer launched Abiraterone Acetate Tablets, 250mg, the generic equivalent to Zytiga. The product launch is expected to help company enhance the business and increase the product portfolio.

In 2020, Dr Reddy's Laboratories Limited, a global drug manufacturer launched Abiraterone Acetate Tablets in the US market. The product launch is expected to help company enhance its business in the US market and strengthen its position in US market.

Enterprises approach towards enhancing the business in developing countries, coupled with factorable business policies is expected to attract major players this is expected to augment the growth of target market. Factors such as high cost associated to development of drug and stringent government regulations related to product approval are factors expected to hamper the growth of global abiraterone acetate drugs market. In addition, lack of developed infrastructure in developing countries for R&D activities is expected to challenge the growth of target market. However, increasing investment in the healthcare sector by major players, high government spending of development of healthcare infrastructure, and rising percentage of clinical trials are factors expected to create new opportunities for players operating in the abiraterone acetate drugs market over the forecast period. In addition, increasing strategic partnership by major players in order to strengthen the distribution channel is expected to support the revenue transaction of the target market.

Segment Analysis by Region

The market in North America is expected to account for major revenue share in the global abiraterone acetate drugs market due to high percentage of people suffering from cancer. Availability of developed R&D infrastructure, rise in clinical trial activities and increasing investment by public players are factors expected to boost the growth of target market. In addition, presence of large number of players operating in the country and introduction of new products is expected to support the target market growth in this region.

The market in Asia Pacific is expected to witness faster growth in the target market due to increasing government spending on healthcare sector. Government if implementing various health related schemas in order to increase awareness among patients and encourage for adoption of better treatment. With the chancing medical regulations developing hospital infrastructure with the focus to deliver enhanced care are factors expected to impact the growth of target market.

Competitive Landscape

The global abiraterone acetate drugs market is highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.

Abiraterone Acetate Drugs Market Segment Analysis, 2020

The global abiraterone acetate drugs market is segmented into dosage form, strength, and distribution channel. The dosage form segment is divided into film-coated tablet and uncoated tablet. Among dosage form the film-coated tablet segment is expected to account for significant revenue share in the global abiraterone acetate drugs market. The distribution channel segment is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. Players operating in the global abiraterone acetate drugs market are Janssen Global Services, LLC, Dr Reddy's Laboratories, Avalon Pharma Pvt Ltd, Amneal Pharmaceuticals, Sterling S.P.A. IT, Aurisco Pharmaceutical, Teva Pharmaceutical Industries Ltd, ScinoPharm Taiwan, Hetero Healthcare Limited, Qilu Pharmaceutical, Genex Pharma, and Mylan N.V.

Market Segmentation

Market By Dosage Form

Film-Coated Tablet
Uncoated Tablet

Market By Strength

125 mg
250 mg
500 mg

Market By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Market By Geography

North America
•    U.S.
•    Canada

Europe
•    U.K.
•    Germany
•    France
•    Spain
•    Rest of Europe

Asia-Pacific
•    China
•    Japan
•    India
•    Australia
•    South Korea
•    Rest of Asia-Pacific

Latin America
•    Brazil 
•    Mexico
•    Rest of Latin America

Middle East & Africa
•    GCC
•    South Africa
•    Rest of Middle East & Africa

TABLE OF CONTENT